OBXHealthcare · Biotechnology

OBX Stock Forecast: Obsidian Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026

$18

−6.08% on the day

The 2 Wall Street analysts covering Obsidian Therapeutics, Inc. hold a median 12-month price target of $42 — +136.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 15 Aug 2026 — in the upper half.

Market cap

$1.1B

Ticker Nerd rank

61 / 100

Median analyst target

$42

Analysts covering

Total return, dividends reinvested

−35.4%

From high

−49.2%

From low

+13.8%

$16

$35

Range since 29 July 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

OBX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Obsidian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026

61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value

Issuance

Quality

Growth

Momentum

Size

Revisions

Accruals

Volatility

Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (19): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OBX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OBX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $42Median $42High $42

The green dot is the last close — the median target sits +136.4% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
5 Aug 2026	Piper Sandler	Initiates	Overweight	$42

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OBX appears on the weeks it earns a place.

Estimates

OBX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Obsidian Therapeutics, Inc. (OBX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: —
Price / book: —
EV / EBITDA: −2.8×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 37.8%
Return on assets: −113.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OBX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
OBXObsidian Therapeutics, Inc.	$1.1B	61
SANASana Biotechnology, Inc.	$1.1B	32
SVRASavara, Inc.	$1.1B	33
WVEWave Life Sciences, Inc.	$1.0B	15
LXRXLexicon Pharmaceuticals, Inc.	$1.0B	69
AVTXAvalo Therapeutics, Inc.	$1.0B	42
MNKDMannKind Corp.	$1.2B	31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Obsidian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OBX news & analysis

Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma

Business Wire · 5 Aug 2026positive

Obsidian Therapeutics announced that the first patient has been enrolled in the registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study evaluating amsoki-cel (formerly OBX-115), an engineered TIL cell therapy, in advanced melanoma.

Why it matters — This marks a clinical milestone for Obsidian's lead engineered TIL cell therapy candidate as it enters a registration-enabling cohort.

FAQ

Frequently asked questions about OBX stock

What is the OBX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Obsidian Therapeutics, Inc. have a median 12-month price target of $42, with estimates ranging from $42 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OBX stock a buy right now?

Of the 2 analysts covering Obsidian Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Obsidian Therapeutics, Inc. 61 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OBX?

As at 15 Aug 2026, Obsidian Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).

Will OBX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +136.4% from the last close, and Ticker Nerd's factor model ranks Obsidian Therapeutics, Inc. 61 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OBX stock forecast for 2030?

No analyst covering Obsidian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $42 to $42 over the next 12 months.

What does Obsidian Therapeutics, Inc. do?

Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on engineered cell and gene therapies for cancer and other intractable diseases.

What is the latest news on OBX?

The most recent item we track (Business Wire, 5 Aug 2026): "Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma". Obsidian Therapeutics announced that the first patient has been enrolled in the registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study evaluating amsoki-cel (formerly OBX-115), an engineered TIL cell therapy, in advanced melanoma.

Company

About Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on engineered cell and gene therapies for cancer and other intractable diseases. The company specializes in tumor-infiltrating lymphocyte (TIL) therapies for solid tumor malignancies, leveraging its proprietary cytoDRiVE platform to enable precise, pharmacologic control of protein activity in therapeutic cells. This controllable architecture is designed to enhance anti-tumor efficacy while managing safety, using FDA-approved small-molecule drugs to regulate the timing and level of protein function within engineered cells. Obsidian’s lead investigational therapy, OBX-115, is an engineered TIL product being evaluated in clinical trials for advanced solid tumors such as melanoma and non-small cell lung cancer. Operating within the oncology segment of the biotechnology and broader healthcare markets, Obsidian Therapeutics works with clinical partners and institutional investors to advance novel cell-based immunotherapies that address limitations of conventional TIL and other adoptive cell therapies. Founded in 2015, the company today plays a specialized role in next-generation oncology therapeutics.

CEO Dr. Madan Jagasia M.D., M.S. · 71 employees · United States · https://obsidiantx.com